Pär Stattin

27.8k total citations · 2 hit papers
419 papers, 16.8k citations indexed

About

Pär Stattin is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Pär Stattin has authored 419 papers receiving a total of 16.8k indexed citations (citations by other indexed papers that have themselves been cited), including 249 papers in Pulmonary and Respiratory Medicine, 143 papers in Oncology and 89 papers in Molecular Biology. Recurrent topics in Pär Stattin's work include Prostate Cancer Treatment and Research (210 papers), Prostate Cancer Diagnosis and Treatment (172 papers) and Cancer, Lipids, and Metabolism (57 papers). Pär Stattin is often cited by papers focused on Prostate Cancer Treatment and Research (210 papers), Prostate Cancer Diagnosis and Treatment (172 papers) and Cancer, Lipids, and Metabolism (57 papers). Pär Stattin collaborates with scholars based in Sweden, United States and United Kingdom. Pär Stattin's co-authors include Anders Bergh, Pernilla Wikström, Hans Garmo, Göran Hallmans, Lars Egevad, Rudolf Kaaks, Jan Adolfsson, David Robinson, Ola Bratt and Jan‐Erik Damber and has published in prestigious journals such as Proceedings of the National Academy of Sciences, JAMA and Journal of Clinical Oncology.

In The Last Decade

Pär Stattin

410 papers receiving 16.4k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Expression of Androgen Receptor Splice Variants in Prostate Cancer Bone Metastases is Associated with Castration-Resistance and Short Survival

2011 381 citations Pär Stattin, Anders Widmark et al. profile →
Epidemiology and Prevention of Prostate Cancer

2021 325 citations Pär Stattin et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Pär Stattin	7.0k	5.0k	4.9k	3.6k	2.2k	419	16.8k
Tomasz M. Beer	10.8k 1.6×	6.1k 1.2×	4.3k 0.9×	4.3k 1.2×	1.7k 0.8×	406	18.0k
M. Scott Lucia	7.7k 1.1×	2.2k 0.4×	3.2k 0.7×	1.8k 0.5×	1.3k 0.6×	193	14.4k
Stephen J. Freedland	17.6k 2.5×	6.5k 1.3×	4.4k 0.9×	5.7k 1.6×	1.7k 0.8×	819	26.2k
Roger A’Hern	5.2k 0.8×	9.4k 1.9×	3.7k 0.8×	5.4k 1.5×	889 0.4×	282	20.5k
Phyllis J. Goodman	6.8k 1.0×	3.5k 0.7×	2.3k 0.5×	1.9k 0.5×	1.7k 0.8×	160	13.2k
Lambertus A. Kiemeney	5.2k 0.7×	3.8k 0.8×	5.2k 1.1×	2.8k 0.8×	1.1k 0.5×	471	21.5k
Meredith M. Regan	7.8k 1.1×	6.7k 1.3×	4.5k 0.9×	6.6k 1.9×	611 0.3×	331	18.4k
Rudolf Kaaks	2.0k 0.3×	6.2k 1.2×	4.9k 1.0×	3.2k 0.9×	2.9k 1.3×	308	18.2k
Neil Fleshner	8.4k 1.2×	3.4k 0.7×	3.3k 0.7×	2.3k 0.6×	1.1k 0.5×	661	16.5k
Judd W. Moul	14.6k 2.1×	3.9k 0.8×	3.9k 0.8×	3.2k 0.9×	1.5k 0.7×	526	20.5k

Countries citing papers authored by Pär Stattin

Since Specialization

Citations

This map shows the geographic impact of Pär Stattin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pär Stattin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pär Stattin more than expected).

Fields of papers citing papers by Pär Stattin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pär Stattin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pär Stattin. The network helps show where Pär Stattin may publish in the future.

Co-authorship network of co-authors of Pär Stattin

This figure shows the co-authorship network connecting the top 25 collaborators of Pär Stattin. A scholar is included among the top collaborators of Pär Stattin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pär Stattin. Pär Stattin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Egevad, Lars, Brett Delahunt, Hemamali Samaratunga, et al.. (2025). Gleason scores provide more accurate prognostic information than grade groups. Pathology. 57(3). 293–296. 2 indexed citations

Strömberg, Ulf, Anders Berglund, Stefan Carlsson, et al.. (2024). Socioeconomic inequality in prostate cancer diagnostics, primary treatment, rehabilitation, and mortality in Sweden. International Journal of Cancer. 155(4). 637–645. 4 indexed citations

Egevad, Lars, Brett Delahunt, Hemamali Samaratunga, et al.. (2024). Prognosis of Gleason score 8 prostatic adenocarcinoma in needle biopsies: a nationwide population-based study. Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin. 484(6). 995–1003. 2 indexed citations

Stattin, Pär, Xiwu Lin, Florence Lefresne, et al.. (2024). Population‐based study of disease trajectory after radical treatment for high‐risk prostate cancer. British Journal of Urology. 134(1). 96–102.

Thomsen, Frederik Birkebæk, Hans Garmo, Lars Egevad, Pär Stattin, & Klaus Brasso. (2024). Temporal trend in risk of prostate cancer death in men with favourable-risk prostate cancer. Scandinavian Journal of Urology. 59. 76–83.

Corsini, Christian, et al.. (2023). Survival Trend in Individuals With De Novo Metastatic Prostate Cancer After the Introduction of Doublet Therapy. JAMA Network Open. 6(10). e2336604–e2336604. 17 indexed citations

Sun, Ming, Josef Fritz, Christel Häggström, et al.. (2023). Metabolically (un)healthy obesity and risk of obesity-related cancers: a pooled study. JNCI Journal of the National Cancer Institute. 115(4). 456–467. 27 indexed citations

Fritz, Josef, Sylvia H. J. Jochems, Tone Bjørge, et al.. (2023). Body mass index, triglyceride-glucose index, and prostate cancer death: a mediation analysis in eight European cohorts. British Journal of Cancer. 130(2). 308–316. 10 indexed citations

Crump, Casey, Pär Stattin, James D. Brooks, et al.. (2023). Risks of alcohol and drug use disorders in prostate cancer survivors: a national cohort study. JNCI Cancer Spectrum. 7(4). 3 indexed citations

10.

Beckmann, Kerri, Hans Garmo, Per Nilsson, et al.. (2020). Radical radiotherapy for prostate cancer: patterns of care in Sweden 1998–2016. Acta Oncologica. 59(5). 549–557. 10 indexed citations

11.

Lissbrant, Ingela Franck, Eugenio Ventimiglia, David Robinson, et al.. (2018). Nationwide population-based study on the use of novel antiandrogens in men with prostate cancer in Sweden. Scandinavian Journal of Urology. 52(2). 143–150. 12 indexed citations

12.

Loeb, Stacy, Yasin Folkvaljon, Jan‐Erik Damber, et al.. (2017). Testosterone Replacement Therapy and Risk of Favorable and Aggressive Prostate Cancer. Journal of Clinical Oncology. 35(13). 1430–1436. 55 indexed citations

13.

Lin, Daniel W., Liesel M. FitzGerald, Rong Fu, et al.. (2011). Genetic Variants in the LEPR , CRY1 , RNASEL , IL4 , and ARVCF Genes Are Prognostic Markers of Prostate Cancer-Specific Mortality. Cancer Epidemiology Biomarkers & Prevention. 20(9). 1928–1936. 55 indexed citations

14.

Hammarsten, Peter, Andreas Josefsson, Stina Häggström Rudolfsson, et al.. (2010). Low Levels of Phosphorylated Epidermal Growth Factor Receptor in Nonmalignant and Malignant Prostate Tissue Predict Favorable Outcome in Prostate Cancer Patients. Clinical Cancer Research. 16(4). 1245–1255. 49 indexed citations

15.

Klein, Robert J., Christer Halldén, Angel M. Cronin, et al.. (2010). Blood Biomarker Levels to Aid Discovery of Cancer-Related Single-Nucleotide Polymorphisms: Kallikreins and Prostate Cancer. Cancer Prevention Research. 3(5). 611–619. 45 indexed citations

16.

Hsu, Fang‐Chi, Jielin Sun, Fredrik Wiklund, et al.. (2009). A Novel Prostate Cancer Susceptibility Locus at 19q13. Cancer Research. 69(7). 2720–2723. 36 indexed citations

17.

Liu, Wennuan, Jishan Sun, Ge Li, et al.. (2009). Association of a Germ-Line Copy Number Variation at 2p24.3 and Risk for Aggressive Prostate Cancer. Cancer Research. 69(6). 2176–2179. 58 indexed citations

18.

Kaaks, Rudolf, Pär Stattin, Stéphanie Villar, et al.. (2009). Insulin-like Growth Factor-II Methylation Status in Lymphocyte DNA and Colon Cancer Risk in the Northern Sweden Health and Disease Cohort. Cancer Research. 69(13). 5400–5405. 25 indexed citations

19.

Sun, Jielin, Siqun L. Zheng, Fredrik Wiklund, et al.. (2008). Sequence Variants at 22q13 Are Associated with Prostate Cancer Risk. Cancer Research. 69(1). 10–15. 79 indexed citations

20.

Stattin, Pär. (2001). Ratios of IGF-I, IGF Binding Protein-3, and Prostate-Specific Antigen in Prostate Cancer Detection. The Journal of Clinical Endocrinology & Metabolism. 86(12). 5745–5748. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact